OurCrowd
VC Fund
Jerusalem, Israel
OurCrowd is a VC fund in Jerusalem focused on Software and Artificial Intelligence. OurCrowd sources and evaluates startup deals and venture funds across multiple sectors to offer direct investment options to its network. Its professionals conduct due diligence and provide market insights for each presented opportunity to assist users in building diversified portfolios. Beyond capital allocation, the entity facilitates strategic introductions and mentorship to support the growth of its portfolio companies. The platform allows for investment across various currencies and includes a reporting system for tracking performance and lifecycle updates.
- Total investments:
- 393
- Last investment:
- Lead investor:
- 16%
- Fund size:
- $230k
- Last fund:
Last updated:
For AI agents: llms.txt
Industries OurCrowd invests in
Stages OurCrowd invests in
Countries OurCrowd invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 20 contacts → | |||
Round size
- Seed
- $604k–$8M
- Series A
- $3M–$22M
- Series B
- $6.1M–$62M
Investment Focus
Industry
- Software 51 (13%)
- Artificial Intelligence 43 (11%)
- Health Care 31 (8%)
- Machine Learning 27 (7%)
- Information Technology 27 (7%)
Stage
- Series B 74 (19%)
- Series A 72 (18%)
- Seed 51 (13%)
- Series C 37 (9%)
- Venture - Series Unknown 37 (9%)
Country
- Israel 121 (31%)
- United States 72 (18%)
- New Zealand 9 (2%)
- Canada 5 (1%)
- Singapore 3 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
David Shore
Vice President, Investor Relations - Canada
|
Vice President, Investor Relations - Canada | Total investments: 0 | Find email | |
Denes Ban
Managing Director, Partner
|
Managing Director, Partner | Total investments: 4 | Find email | |
Etai Kramer
Managing Director, Head Funds
|
Managing Director, Head Funds | Total investments: 1 | Find email | |
Lenny Roth
Partner
|
Partner | Total investments: 0 | Find email | |
Steven Blumgart
Chairman
|
Chairman | Total investments: 1 | Find email | |
| See all 20 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| BloomX is an AI pollination solution for crops in which pollination is a limiting factor for their yield. The company allows growers to increase their revenue by enlarging yields in existing crops and improving fruit quality.BloomX's vision is to provide an AI-based pollination solution that addresses each crop’s pollination needs bymimicking the natural pollination process and enhancing it using technology. Bumblebee was founded in 2019 and is headquartered in Tel Aviv, Israel. | $13M / Series A / Oct 08, 2026 | ||
| N.Light is a Metaverse 3D design software that allows individuals to effortlessly turn their ideas into reality. | $10.6M / Venture - Series Unknown / Aug 10, 2026 | ||
| Hemispheric develops fundamental AI technologies aimed at deciphering brain activity for innovative applications. | $52M / Series A / Jul 15, 2026 | ||
| Corgi Insurance Services, Inc. ("Corgi") is an American technology company that operates an artificial intelligence (AI)-powered insurance carrier based in San Francisco, California. Corgi Insurance develops and operates a fully integrated insurance stack using AI agents to automate traditional carrier operations, becoming the world’sfirst “AI insurance company.” The company owns multiple subsidiaries operating under a dog-themed naming convention. | $160M / Series B / May 06, 2026 | ||
| PhenOlives transforms olive oil waste into nutritious, gluten-free olive flour that retains the health benefits of olive oil. The company employs a patented process to create a high-fiber ingredient suitable for various baking and cooking applications. | $270K / Seed / May 04, 2026 | ||
| Xage Security blocks cyberattacks, secures local and remote access, and protects all assets across the enterprise. | $15M / Venture - Series Unknown / Mar 18, 2026 | ||
| Winn.AI handles all of your sales busywork so you can type less and win more. | $18M / Series A / Feb 11, 2026 | ||
| Omnix Medical is dedicated to the development and commercialization of highly effective antibiotic agents against resistant pathogenic bacterial strains. Omnix is addressing an enormous and rapidly growing threat to public health, represented by millions worldwide, who suffer from infections associated with resistant bacteria. Omnix’s technologywill tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide. | $25M / Series C / Oct 15, 2025 | ||
| Leo™ is the world's first engineering design copilot, empowering engineers and designers to turn ideas into products in seconds. Leo's generative AI platform transforms text, sketches, specs, and CAD constraints into DFMA-optimized, full-assembly 3D CAD models, saving companies up to 70% of their engineering time and cost. Leading AIresearchers and mechanical engineers from MIT, Technion, Microsoft, and Elbit Systems founded Leo in 2023. | $5M / Seed / Sep 02, 2025 | ||
| RepAir develops a Direct Air Capture system based on a proprietary electrochemical cell technology that can capture CO2 from the air in gigaton scale. Powered solely by renewable energy, our system can be deployed at the site of carbon storage or utilizations, saving arable land and avoiding CO2 transport. | $15M / Series A / Apr 24, 2025 | ||
| See all 393 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does OurCrowd invest in?
OurCrowd invests primarily in Software, Artificial Intelligence and Health Care startups, most often at Series B and Series A stage. Most of the 393 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does OurCrowd invest in?
OurCrowd typically joins rounds of $604k–$8M at Seed, $3M–$22M at Series A and $6.1M–$62M at Series B. These are whole funding-round sizes, not OurCrowd's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds OurCrowd took part in.
How do I contact OurCrowd?
Public channels for OurCrowd include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at OurCrowd?
The team at OurCrowd includes David Shore (Vice President, Investor Relations - Canada), Denes Ban (Managing Director, Partner) and Etai Kramer (Managing Director, Head Funds), among 20 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
